Feed MDWD
MD

MediWound Ltd.

MDWD · NASDAQ

$13.40 -0.15% (-$0.02)
1M +1.44%
Market Cap $171.5M
P/E Ratio -
Div. Yield -
ROE 47.24%
Piotroski F-Score Weak
1/9
Valuation
20 /100
Expensive
P/B 4.81x
P/S 14.46x
EV/FFO N/A
Growth
22 /100
Declining
Book val. growth 58.71%
Rev. growth 13.82%
FCF growth N/A
Profitability
4 /100
Weak
Op. margin 267.86%
Gross margin 15.46%
FCF margin 239.28%
Quality
2 /100
Poor
ROA 28.07%
ROIC 70.36%
Asset turnover 0.17x
Debt
69 /100
Low
Int. coverage -18.64x
Debt/Equity 0.27x
Current ratio 2.32x
Stability
18 /100
Unstable
EPS volatility 209.25%
Beta 0.14x
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre MDWD
Online

Despre companie

MediWound Ltd. (MDWD) is a biotechnology company focused on the development of innovative therapeutic products for the treatment of skin injuries, burns, and other dermatological conditions. Their main product is an enzymatic medicinal preparation called NexoBrid®, which is used for the removal of burned tissue and promotes wound healing. MediWound Ltd. is known for its research and development of new treatment methods aimed at improving the treatment of patients with burns and other skin injuries. The company also offers additional therapeutic products and services for the healthcare sector. MediWound Ltd. (MDWD) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on the treatment of skin injuries and burns.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Ofer Gonen

Employees

121

Headquarters

Yavne

Evenimente viitoare

19 NOV.

Earnings

Upcoming earnings report

60d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.